- Exchange: New York
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Eli Lilly & Co
+ Add to WatchlistLLY:US
55.9000 USD 0.0400 0.07%
Share
As of 20:04:04 ET on 05/17/2013.
More on LLY
News for Eli Lilly & Co (LLY)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Lundbeck’s Brintellix Is More Effective in Higher Dose in Study
- Lilly, ThyssenKrupp, Adidas, AMD: Intellectual Property
- Canada Supreme Court Won’t Hear Eli Lilly Zyprexa Appeal
- Jolie Mastectomy Fuels Debate on Breast Cancer Treatment
- Jolie Has Double Mastectomy to Thwart Cancer Gene Risk
- Lilly CEO Lechleiter Has Surgery to Repair Heart
- Lilly Stops Trial of Lymphoma Drug Due to Ineffectiveness
- Bristol-Myers, Disney, Google: Intellectual Property
- Congress Members Sprint for Money to Lobby After Election
- Bristol-Myers Sues Genentech Over ‘Cabilly’ Patents
- Baxter Immunoglobulin Fails to Aid Alzheimer’s Patients
- Lilly’s CEO Lechleiter Plans Surgery for Dilated Artery
- Oxford Works With Drugmakers to Reverse 90% Trial Failure Rate
- Merck Cuts Profit Forecast as Buyback Boosted $15 Billion
- Eli Lilly Sues J&J for Patents Rights in Alzheimer Drug Race
- Lilly Oncology to Release New Pipeline Data at ASCO 2013 Published May 14, 2013
- Lilly Provides Update on CEO Dr. John Lechleiter Published May 14, 2013
- Third Rock Ventures Expands and Strengthens Team Published May 14, 2013
- Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma Published May 10, 2013
- Sears Holdings Names Jeff Balagna Executive Vice President And Chief Information Officer Published May 09, 2013
- LILLY (ELI) & COMPANY: Doc re Form 8K Filing Published May 08, 2013
- Eli Lilly and Company Files a Form 8-K Published May 08, 2013
- Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery Published May 08, 2013
- LILLY (ELI) & COMPANY: CEO Lechleiter to undergo surgery Published May 07, 2013
- Retrospective analysis of linagliptin data in sub-populations with type 2 diabetes presented at AACE 22nd Annual Scientific & Published May 06, 2013
- Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery Published May 06, 2013
- Lilly Declares Second-Quarter 2013 Dividend Published May 06, 2013
- LILLY (ELI) & COMPANY: 1st Quarter Results Published May 03, 2013
- LILLY (ELI) & COMPANY: Doc re Proxy Statements Published May 03, 2013
- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type Published May 02, 2013
- Lundbeck’s Brintellix Is More Effective in Higher Dose in Study
- SAC Says Cooperation With U.S. No Longer ‘Unconditional’
- Credit Swaps in U.S. Fall as Leading Indicators, Sentiment Rise
- Puma Biotech Gains After Rival Drug Data Show No Threat
- J&J Will Stop Sales of Metal-on-Metal Hip Replacements
- Sanofi, French Government at Odds Over Fate of Research Site
- Expected Earnings Growth for Industries in Stoxx 600
- Petrobras, Merck Lead $54 Billion of Company Bond Sales in U.S.
- Merck KGaA Doesn’t Rule Out Pursuing Lung-Cancer Vaccine
- Glaxo Sees Emerging Market Price Cuts Driving Drug Volume Growth
- Final Soccer World Cup Sponsor to Spend $50 Million in 15 Months
- Japan REITs Favored, May Gain 25%, Freeze Says
- Billionaire Frost Props Up Prolor Bid With Stock Buys
- Bristol-Myers Drug Cocktail Stymies Melanoma Tumors
- U.S. Stock Options With Biggest Changes in Implied Volatility
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page